Navigation Links
Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
Date:10/1/2013

id analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.

Safe Harbor Statement 
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the analyses of the Global PBC Study Group data and the results thereof, the relationship between ALP and bilirubin and adverse clinical outcomes, the clinical utility of the POISE trial selected endpoints and any potential consensus relating thereto, clinical, preclinical and regulatory developments for our product candidates, the anticipated results of our clinical and preclinical trials and other development activities, and our strategic directives under the caption "About Intercept." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the initiation, cost, timing, progress and results of Intercept's development activities, preclinical studies and clin
'/>"/>

SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
2. Predilytics Secures Additional Funding and Expands Board of Directors
3. Auxilium Pharmaceuticals, Inc. Raises $50 Million In Additional Financing
4. Omeros Reports Additional Positive Results from OMS824 Program
5. AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares
6. Additional Results From Phase 3 Trial Of IVIG In Alzheimers Reported At Alzheimers Association International Conference
7. 14 Additional Hospitals Select CareFusion Pyxis ES Platform To Improve Medication Management Efficiency, Safety
8. MediScripts and The Jed Foundation Team Up to Offer Physicians Additional Resources to Support Emotional Health of College-Age Students
9. C&J Industries Announces Additional Expansion
10. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
11. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: North America Aesthetic Lasers ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North ... to 2020 Summary GlobalData,s new report, ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a ... Phase 3 study required for New Drug Application (NDA) ... 140 patients has greater than 90% power to detect ... to enrol additional patients. QRxPharma anticipates completing analysis of ...
... or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that ... clearance from the U.S. Food and Drug Administration (FDA). ... variant of the Unitract™ 1mL Insulin Syringe for which ... syringes which are primarily used by people with diabetes, ...
Cached Medicine Technology:QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 3Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 2Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 3
(Date:8/30/2014)... Skmen.com, a well-known clothing manufacturer, has announced its promotion ... middle of September, all the company’s new and old ... 30 percent off. , As a matter of ... made and come with quality guarantees. They can certainly ... popular for its fashionable, high quality clothes for men ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 Information ... Pros company to introduce better prices to consumers in ... plans can be found when using the open system ... national lookup system available to use this year can ... insurance based on general location and not from medical ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 Daily ... Carter, called the Make Him Desire You program, who shows ... heart. , The author of this method says that the ... guys. , The Make Him Desire You review indicates that ... reveals amazing insider advice and his great techniques to make ...
(Date:8/30/2014)... August 30, 2014 Daily Gossip reveals in ... Infection is a method created by Sarah Summer, who can ... The author of this new program actually had to deal ... sufferer to be able to access it, in an all-natural ... determination in finding an effective cure for yeast infection. The ...
Breaking Medicine News(10 mins):Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2
... Celator Pharmaceuticals today announced that new data ... in consolidation treatment for leukemia and of CPX-1 ... agents for the treatment of colorectal cancer were ... American Association for Cancer Research (AACR) in Denver, ...
... REDWOOD CITY, Calif., April 22 AcelRx Pharmaceuticals, ... Phase 2 clinical trial of ARX-02, a proprietary ... pain control. The primary objective of this multicenter, ... tolerability and efficacy of ARX-02 relative to placebo ...
... OAK BROOK, Ill., April 22 The ... of Minnesota have agreed to conditions for ... receive certain services from DeCare Dental following ... certain business functions that DeCare previously performed ...
... on the list. , ... Newport Beach, CA (Vocus) April 22, 2009 ... of four hospitals in Los Angeles and Orange Counties and one of ... as reported by AARP The Magazine. The designation of a "top hospital" ...
... is committed to providing people with skin care ... practical advice and helpful insights are provided by ... devotion to cosmetic dermatology. The content is written ... wide range of practical advice. Key portions of ...
... its commitment to seniors on Medicaid. New Jersey ... Assisted Living Concepts, revealed a history of evictions when ... , WESTBURY, N.Y., April 22 Raphael Weiss, Managing ... ( www.AmberCourtAL.com ), assured that his ...
Cached Medicine News:Health News:Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research 2Health News:Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research 3Health News:AcelRx Announces Initiation of Phase 2 Cancer Breakthrough Pain Program 2Health News:Delta Dental Plans Association and Delta Dental of Minnesota Agree to Conditions Regarding Supplier 2Health News:Hoag named in top 125 hospitals by Consumers' CHECKBOOK as reported by AARP The Magazine 2Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2Health News:Amber Court Assisted Living Communities Reaffirms its Commitment to Seniors on Medicaid 2
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... SEAMGUARD® Staple Line Reinforcement Material is ... postoperative pulmonary air leaks and as ... This inert, biocompatible, ePTFE material requires ... easy to load and fire and ...
... for the repair of abdominal hernias. It ... two distinct sides. One side of ... of sodium hyaluronate and carboxymethylcellulose (similar to ... side is bioresorbable, providing a temporary physical ...
... The Hernia Repair Company, we recognize that ... limited fibrous tissue in-growth between the prosthesis ... polypropylene mesh. Like all the products in ... produces a clinically proven, versatile repair.,The Reconix ...
Medicine Products: